The CHDI Foundation, Inc. (CHDI), a privately-funded research organization, has extended its collaboration with Evotec AG through 2015. Evotec will provide medicinal chemistry, in vitro and in vivo pharmacology, and compound management. The contract has a potential value of $41 million in research payments for Evotec.
"We are delighted that CHDI, an organization dedicated solely to the quest to discover novel drugs against Huntington's disease, continues to work in partnership with Evotec," said Dr. Mario Polywka, chief operating officer of Evotec. "This collaboration is an excellent example of how companies, including foundations such as CHDI, can access Evotec's platform suite of technologies, capabilities and strong disease biology expertise, to drive their drug discovery efforts."
"CHDI partners with a global network of investigators from the academic, biopharmaceutical, and service sectors to execute our drug discovery and development efforts," said Dr. Robert Pacifici, chief scientific officer at CHDI. "Evotec represents one of our largest and longest standing relationships with a contract research organization. We are delighted that, with the renewal of our contract, CHDI and Evotec will be able to continue our productive interactions and drive our therapeutic programs forward."